Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA’s 2020 User Fee Calendar Still Holds Promise Of Merry Novel Approval Count

Executive Summary

The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.

You may also be interested in...



As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran

Novartis has pooled cholesterol control and safety data, but will have to wait longer for cardiovascular outcomes readout.

Roxadustat Stacks Up To Darbepoietin In Non-Dialysis Anemia

Astellas’s oral HIF-PH inhibitor shows non-inferiority to one established ESA in head-to-head trial and while there were cardiovascular benefits, the picture is complex.

US FDA’s Median Review Time For Novel Drugs Held Steady In 2020

Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.

Topics

Related Companies

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel